Cancer Origin Cell Study: What Research Now Reveals

Ask most people where cancer comes from and they'll name an organ — the breast, the bowel, the lung. That's understandable, but it's only half the story. Cancer doesn't just come from an organ. It comes from a specific type of cell within that organ, and which cell it starts in turns out to matter enormously.

This field — cancer cell-of-origin research — has been building for decades but has accelerated sharply in recent years. The findings are starting to reach clinical practice, and if you're navigating a cancer diagnosis or supporting someone who is, understanding this shift could change the questions you ask your doctor. Finding a specialist physician who understands molecular oncology is worth prioritising, especially for complex or recurrent cancers

The Basic Idea: Not All Cells Are Equal

The human body contains around 37 trillion cells, but they are not all the same. Different tissues contain different cell types, and within those tissues, some cells are more vulnerable to becoming cancerous than others.

Stem cells — cells that can divide and renew themselves repeatedly — are particularly significant here. Because they live longer and divide more often than specialised cells, they have more opportunities to accumulate the genetic damage that drives cancer. Many researchers now believe that the majority of cancers originate in stem cells or early progenitor cells (cells that are one step away from becoming a specialised cell type).

This matters clinically because stem cells carry different molecular signatures than other cells — and those signatures can persist in the tumour even after it has grown and spread. If you're being assessed for an unusual or aggressive cancer, specialist diagnostics and pathology services that include molecular testing may provide more actionable information than standard imaging alone.

Why Two "Identical" Cancers Can Behave So Differently

Here's something that genuinely surprised me when I first read the research: two breast cancer tumours that look completely identical under a microscope can have dramatically different outcomes — one responds well to treatment, the other spreads rapidly. Cell-of-origin research is helping explain why.

If a tumour originates in a luminal epithelial cell (a cell lining the milk ducts), it tends to behave differently from one originating in a basal cell (a deeper layer of breast tissue), even if they both get categorised as "breast cancer" in standard pathology. The originating cell type influences the tumour's biology — how fast it grows, which proteins it expresses, which drugs it responds to, and how likely it is to metastasise (spread to other parts of the body).

In clinical practice, this is one of the reasons why oncologists are increasingly cautious about applying treatment protocols based purely on tumour location. The same chemotherapy or targeted therapy regimen can produce very different results in two patients with the "same" cancer — and the originating cell type is one significant reason why.

Colorectal Cancer: A Case Study in Cell-of-Origin Science

Bowel cancer (colorectal cancer) has been one of the most studied areas for cell-of-origin research. The colon contains multiple cell types, but cancers most commonly arise from intestinal stem cells sitting at the base of structures called crypts — tiny pocket-shaped units that line the gut wall.

What's been discovered is that the position of the cell within the crypt matters. Stem cells at the very base of the crypt are under tighter molecular regulation, while cells slightly higher up — transit-amplifying cells — are more vulnerable to early cancerous mutations under certain conditions.

Dietary factors, inflammation, and gut microbiome composition all interact with these cells in ways that influence cancer risk. This is why gastroenterologists are becoming increasingly important in cancer prevention conversations, not just diagnosis. If you have symptoms like persistent changes in bowel habits or unexplained abdominal discomfort, a diagnostic centre near you can arrange the relevant tests on referral.

Breast Cancer and the Basal vs Luminal Distinction

The breast cancer field has moved furthest in applying cell-of-origin insights clinically. The molecular subtypes of breast cancer now used in standard practice — luminal A, luminal B, HER2-enriched, triple-negative — partly reflect differences in the originating cell population.

Triple-negative breast cancer, which lacks three key hormone receptors and is notoriously harder to treat, shows strong features consistent with a basal cell origin. This has driven research into therapies targeting basal cell biology specifically, rather than the hormone pathways that work well in luminal cancers.

Women with a family history of breast cancer — especially at younger ages — should discuss personalised cancer screening timelines with a gynaecologist or specialist. Cell-of-origin research is one reason why inherited genetic mutations like BRCA1 are now understood to preferentially give rise to specific tumour subtypes, not just breast cancer in general.

The Brain Tumour Question

Glioblastoma — the most aggressive form of brain cancer — has also been studied through a cell-of-origin lens. Research suggests it may originate from neural stem cells or glial progenitor cells, both of which sit in specific regions of the brain.

This has implications for surgery: if the originating cell population isn't removed, even a technically successful surgery may leave behind cells capable of regenerating the tumour. It's one reason why neurological specialists and neurosurgeons at experienced centres approach glioblastoma resection differently from other brain surgeries.

For families dealing with a brain tumour diagnosis, hospitals with neurology and neurosurgery departments that have experience in molecular tumour classification are the right setting for treatment planning.

What This Means for Cancer Treatment

The practical upshot of all this research is a gradual but real shift from location-based cancer classification to biology-based classification. Instead of treating "lung cancer," oncologists increasingly treat specific molecular subtypes of lung cancer — some of which share more in common with cancers from other organs than with each other.

Targeted therapies (drugs designed to hit a specific molecular target rather than all rapidly-dividing cells) are the main clinical beneficiary of this shift. Immunotherapy selection is also increasingly informed by molecular tumour profiling. If you're on or being considered for cancer treatment at a specialist hospital, ask your oncologist whether molecular profiling of your tumour has been done or is available.

The same principle is expanding into surgical planning for cancer — understanding where a tumour originated can inform how aggressively surgeons need to approach margins and which surrounding tissue is most at risk of micro-invasion.

Liquid Biopsies and Future Early Detection

One of the most promising applications of cell-of-origin research is in liquid biopsy — blood tests that detect fragments of tumour DNA circulating in the bloodstream. Because tumours shed DNA that carries the molecular signature of their cell of origin, these tests have the potential to identify not just that cancer is present, but what type it is and where it started — before symptoms appear.

This isn't routine yet, and access varies enormously depending on which country and which hospital you're at. But it's moving fast. Pairing technology-driven diagnostics with clinical expertise is where early cancer detection is heading.

For people with strong family histories, speaking with a general physician about early screening options is a reasonable proactive step now — not something to wait on.

The Mental Load of Complex Cancer Science

Something worth acknowledging: for patients and families, the increasing complexity of cancer biology can feel overwhelming rather than reassuring. When a diagnosis comes back and the oncologist starts talking about molecular subtypes and originating cell populations, it can feel like the language of certainty has been replaced by probability and nuance.

That experience is real, and it's worth naming. Mental health support during cancer treatment — whether through individual counselling, peer support, or psychiatry — is not a secondary concern. If you're struggling to process a diagnosis or treatment plan, talking to a mental health professional should be part of your care, not something you get around to later.

And if getting access to any of these services feels difficult, home visit doctors can provide an initial assessment and referral pathway without requiring you to travel when you're unwell.